Femasys Showcases Fertility Innovations at ASRM 2026 Congress
Event summary
- Femasys Inc. will exhibit at the ASRM 2026 Scientific Congress & Expo from October 24–28 in Baltimore.
- The company will highlight FemaSeed® Intratubal Insemination (ITI) and FemVue® diagnostic solution at booth #513.
- Kathy Lee-Sepsick, CEO, emphasizes expansion into OB/GYN practices to offer earlier fertility evaluation and treatment options.
- FemBloc®, a non-surgical permanent birth control solution, is advancing toward U.S. FDA approval through the ongoing FINALE pivotal trial.
The big picture
Femasys' participation in the ASRM 2026 Congress underscores its strategic push to expand its fertility portfolio beyond traditional reproductive endocrinology practices. The company's focus on integrating its solutions into OB/GYN workflows aligns with broader industry trends toward earlier intervention and cost-effective fertility treatments. The ongoing development of FemBloc further positions Femasys as a key player in the non-surgical permanent birth control space, with potential regulatory milestones on the horizon.
What we're watching
- Market Expansion
- How Femasys' integration into OB/GYN practices will affect its market penetration and revenue growth.
- Regulatory Progress
- The pace at which FemBloc advances through the FDA approval process and its potential impact on the company's valuation.
- Competitive Positioning
- Whether Femasys can sustain its competitive edge with FemaSeed and FemVue in an increasingly crowded fertility solutions market.
